We aim to develop new technologies to enhance the therapeutic potency of cell-based therapies. With support from the Marcus Center for Therapeutic Cell Characterization and Manufacturing (MC3M) we are utilizing high performance liquid chromatography-mass spectrometry (HPLC-MS/MS) to characterize the anti-inflammatory potential of mesenchymal stem cell (MSCs) based on metabolism of membrane sphingolipid (SLs). We use multi-variate analysis of lipidomic network profiles and cutting imaging analysis methods to gain mechanistic insight into the origin of observed changes in lipid biomarkers and SL signaling molecules. This analysis will lead to new technologies to predict, monitor, and adjust therapeutic cell potency during culture and expansion. We are also interested in optimizing new 3D biomaterials and bioreactors to specialize culture conditions for control of cell quality.